Navigation Links
Astellas and Medivation Enter Into Worldwide Agreement to Co-Develop and Co-Commercialize MDV3100 for the Treatment of Prostate Cancer
Date:10/27/2009

TOKYO and SAN FRANCISCO, Oct. 27 /PRNewswire-FirstCall/ -- Astellas Pharma Inc. ("Astellas") and Medivation, Inc. (Nasdaq: MDVN) announced today that they have entered into a global agreement to develop and commercialize MDV3100, Medivation's investigational drug for the treatment of prostate cancer. MDV3100 is currently being evaluated in the Phase 3 AFFIRM clinical trial in men with castration-resistant prostate cancer who were previously treated with docetaxel-based chemotherapy.

Under the terms of the agreement, Medivation will receive an up-front cash payment of $110 million. Medivation is also eligible to receive payments of up to $335 million upon the attainment of development and regulatory milestones plus up to an additional $320 million in commercial milestone payments. The companies will collaborate on a comprehensive development program that will include additional studies to develop MDV3100 for both late- and early-stage prostate cancer. Subject to receipt of regulatory approval, the companies will jointly commercialize MDV3100 in the U.S. The companies will share equally all U.S. development costs, commercialization costs, and profits. Astellas will have responsibility for developing and commercializing MDV3100 outside the U.S. and will pay Medivation tiered double-digit royalties on ex-U.S. sales.

"We are pleased to initiate a great partnership with Medivation," stated Masafumi Nogimori, president and chief executive officer of Astellas. "We believe that MDV3100 has the unique potential to establish a new treatment approach for prostate cancer. Astellas already has the global expertise in urology and the strong commitment to focus on oncology. This partnership is a significant milestone to further expand our business in urology and to establish our franchise in oncology."

"We are excited t
'/>"/>

SOURCE Medivation, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Medivation Announces Initiation of Phase 3 Clinical Trial of MDV3100 in Advanced Prostate Cancer
2. Medivation Announces Positive New Efficacy Data From Phase 1-2 Trial of MDV3100 in Advanced Prostate Cancer Patients
3. Pfizer and Medivation Initiate Phase 3 Trial of Dimebon Added to Donepezil in Patients with Alzheimers Disease
4. Medivation Completes Enrollment of Phase 1-2 Trial of MDV3100 in Castration-Resistant Prostate Cancer Patients
5. Medivation Presents Positive New Data on Dimebons Long-Term Efficacy and Novel Mechanism of Action at the International Conference on Alzheimers Disease
6. Medivation Announces Publication in The Lancet of Dimebon Pivotal Trial Results in Alzheimers Disease
7. Medivation Announces Positive Top-Line Results From Phase 2 Dimebon Study in Huntingtons Disease
8. Medivation to Host Conference Call at 5 p.m. EDT Monday to Discuss Top-Line Phase 2 Study Results in Huntingtons Disease
9. Medivation Initiates Second Pivotal Phase 3 Trial of Dimebon(TM) in Patients With Alzheimers Disease
10. Medivation Announces Presentation of Positive MDV3100 Clinical Data in Castration-Resistant Prostate Cancer Patients at 44th ASCO Annual Meeting
11. Medivation Announces Presentation of MDV3100 Clinical Data in Patients With Castration-Resistant Prostate Cancer at 44th American Society of Clinical Oncology Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , July 11, 2014 Research ... addition of the "Immunoprotein Diagnostic Testing Market ... the highest CAGR of 6% and is expected ... report to their offering. ... immunoprotein diagnostic testing has been segmented according to ...
(Date:7/11/2014)... Neurelis, Inc. ("Neurelis") today announced an agreement ... held by Biotie to purchase Neurelis, clearing the way ... diazepam) for pediatric and adult epilepsy patients who experience ... Biotie has advanced the development program for NRL-1 and ... work required for NDA submission to the FDA.  Given ...
(Date:7/10/2014)... , July 10, 2014  The U.S. Department ... three-year grant to University Hospitals (UH) Case Medical Center ... new national model aimed at improving care for patients ... Care," the project will test a unique model developed ... with late-stage disease, significant comorbidities, or demonstrated need for ...
Breaking Medicine Technology:Immunoprotein Diagnostic Testing Market - Forecasts to 2019: Expected to grow at the highest CAGR of 6% and is expected to be valued at USD 4,943.0 million 2Neurelis Regains Rights to Intranasal Diazepam Program 2Neurelis Regains Rights to Intranasal Diazepam Program 3University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 2University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 3University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 4
... BEACH, Calif., Jan. 25, 2011 Every business needs a ... others use a differentiation advantage. Hospitals are not immune from ... Dr. Barry Friedberg says if hospitals want ... institute the use of a brain monitor in all surgeries ...
... an innovative medical technology company focused on the treatment ... Relations, LLC of Bridgewater, N.J., as its public relations ... for the Aerocrine brand; most immediately surrounding the NIOX ... available to measure exhaled nitric oxide (eNO) to aid ...
Cached Medicine Technology:If Hospitals Want a Competitive Advantage - Use Brain Monitors in Surgeries Requiring Sedation says Renowned Anesthesiologist 2R&J Public Relations Named Agency of Record for Aerocrine, Inc. 2
(Date:7/11/2014)... (PRWEB) July 11, 2014 Butler Mobility has ... Inclined Platform Lifts . Previously the two standard ... five new beautiful earth tone colors as standard colors at ... well in the home but will enhance the beauty of ... for any home color scheme or individual décor. , The ...
(Date:7/11/2014)... July 11, 2014 Microbiology testing is ... in-vitro diagnostics industry, which is expected to pose the ... The sector owes its growth to the ongoing spread ... health worldwide and a major factor leading to the ... of bio-terrorism, and a broader availability of immunosuppressants, among ...
(Date:7/11/2014)... Rochester, NY (PRWEB) July 11, 2014 ... Surgery ’s own, Dr. William Koenig, has topped a ... his peers, he has performed over 400 successful procedures ... , Dr. Koenig is well known across the country ... His exceptional safety record has long been the foundation ...
(Date:7/11/2014)... Ticket Down is a reliable source for cheap ... comes to the summer concert schedule, it just isn’t complete without ... of the biggest names in country music and one of the ... his “That’s My Kind of Night” tour featuring Lee Brice and ... through the rest of the summer and into the fall includes ...
(Date:7/11/2014)... July 11, 2014 Biostimulants are widely ... in turf and ornamentals. These also help turf and ... length of roots. Turf, ornamentals, and flowers appear healthy ... this usage has increased from the last few years. ... and ornamentals is Europe, with around 40% share in ...
Breaking Medicine News(10 mins):Health News:Butler Mobility Products Announces Five New Standard Colors for Their Inclined Platform Lifts 2Health News:World Virology and Bacteriology Testing Sector Discussed in Comprehensive VPG Research Report Published at MarketPublishers.com 2Health News:World Virology and Bacteriology Testing Sector Discussed in Comprehensive VPG Research Report Published at MarketPublishers.com 3Health News:Rochester Surgeon Hits Milestone with Keller Funnel 2Health News:Luke Bryan Ticket Prices Slashed at Concord Pavilion 2Health News:Luke Bryan Ticket Prices Slashed at Concord Pavilion 3Health News:Biostimulants Market in Turf and Ornamentals is Expected to Reach $ 3.8 Billion by 2018 - New Report by MicroMarket Monitor 2Health News:Biostimulants Market in Turf and Ornamentals is Expected to Reach $ 3.8 Billion by 2018 - New Report by MicroMarket Monitor 3
... virologist has blamed the resurgence of polio in India on ... used// for its eradication. ,Polio cases have risen ... of last year. Appearance of Indian strains of the virus ... has alarmed the World Health Organization (WHO). ,Thekakkara ...
... a motive of enabling women the best possible avenues to ... free breast cancer screening// in Dubai, scheduled to begin next ... in the emirate, UAE nationals, expatriates and visitors, to avail ... is absolutely essential to achieve better treatment outcomes. ...
... year's World Heart Day -- "How Young is Your Heart" ... Chennai// : "Be Proactive, Get the Facts". ,According ... "Learning that you or someone you love has a serious ... hope than ever. By taking a proactive role in learning ...
... in Wales are calling on the National Assembly for Wales ... release// patients from a heavy financial burden. ,Welsh ... to park at hospitals is an indirect tax on healthcare. ... clinics do so by car. Often, these people have to ...
... plays a central coordinating role towards the development of diabetes//. ... protein, calcineurin, is vital to the proper functioning of the ... ,This protein has been found to be responsible for ... to diabetes. This study in mice has led to the ...
... always been a blessing for the HIV patients, but new ... ARV’s are capable of halting// the progress of mental illness, ... known that HIV-infection could lead to mental illness. Nearly 40% ... Dr Michelle Rogers, a psychiatrist, says: "There were several really ...
Cached Medicine News:Health News:Polio Outbreak in India due to Vaccine Failure, Says Expert 2Health News:This World Heart Day, Be Proactive, Get the Facts 2Health News:This World Heart Day, Be Proactive, Get the Facts 3Health News:Abolish Car Parking Charges at Welsh Hospitals, says BMA Cymru Wales 2Health News:Abolish Car Parking Charges at Welsh Hospitals, says BMA Cymru Wales 3Health News:Abolish Car Parking Charges at Welsh Hospitals, says BMA Cymru Wales 4
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: